Stereotactic Body Radiotherapy for Localized Kidney Cancer

Rich, Benjamin; Noy, Miguel; Pra, Alan Dal

doi:10.1007/s11934-022-01125-6

Cited by 6 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, stereotactic body radiation therapy (SBRT) is increasingly utilized in the management of localized kidney cancers, particularly for patients who are not surgical candidates. A narrative review of SBRT [47] underlines the safety and efficacy of it in the management of renal tumors (a disease previously thought to be radioresistant). According to the studies included in the review, SBRT can be utilized successfully in the treatment of large renal tumors (>5 cm) and local control is greater than 90%, with rare grade 3 or 4 toxicity and no grade 5 toxicity.…”

Section: Discussionmentioning

confidence: 99%

“Could Patient Age and Gender, along with Mass Size, Be Predictive Factors for Benign Kidney Tumors?”: A Retrospective Analysis of 307 Consecutive Single Renal Masses Treated with Partial or Radical Nephrectomy

Baio

Molisso²,

Caruana

et al. 2023

Bioengineering

View full text Add to dashboard Cite

Due to the increased use of common and noninvasive abdominal imaging techniques over the last few decades, the diagnosis of about 60% of renal tumors is incidental. Contrast-enhancing renal nodules on computed tomography are diagnosed as malignant tumors, which are often removed surgically without first performing a biopsy. Most kidney nodules are renal cell carcinoma (RCC) after surgical treatment, but a nonnegligible rate of these nodules may be benign on final pathology; as a result, patients undergo unnecessary surgery with an associated significant morbidity. Our study aimed to identify a subgroup of patients with higher odds of harboring benign tumors, who would hence benefit from further diagnostic examinations (such as renal biopsy) or active surveillance. We performed a retrospective review of the medical data, including pathology results, of patients undergoing surgery for solid renal masses that were suspected to be RCCs (for a total sample of 307 patients). Owing to the widespread use of common and noninvasive imaging techniques, the incidental diagnosis of kidney tumors has become increasingly common. Considering that a nonnegligible rate of these tumors is found to be benign after surgery at pathological examination, it is crucial to identify features that can correctly diagnose a mass as benign or not. According to our study results, female sex and tumor size ≤ 3 cm were independent predictors of benign disease. Contrary to that demonstrated by other authors, increasing patient age was also positively linked to a greater risk of malign pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

“Could Patient Age and Gender, along with Mass Size, Be Predictive Factors for Benign Kidney Tumors?”: A Retrospective Analysis of 307 Consecutive Single Renal Masses Treated with Partial or Radical Nephrectomy

Baio

Molisso²,

Caruana

et al. 2023

Bioengineering

View full text Add to dashboard Cite

show abstract

“…This includes partial nephrectomy that removes only the cancerous portion of the kidney, while radical nephrectomy removes the entire kidney [9]. Further treatments for kidney cancer comprise of radiation therapy, chemotherapy, targeting medicines, cryoablation, radiofrequency ablation and microwave ablation [10][11][12]. Moreover, in an effort to gain insight into targeting therapy, engineering EVs show potentially effective vehicles against RCC.…”

Section: Extracellular Vesicles (Evs) In Kidney Cancermentioning

confidence: 99%

Kidney Cancer and Potential Use of Urinary Extracellular Vesicles

Le,

Munir,

Kim

et al. 2024

Oncol.Rev.

View full text Add to dashboard Cite

Kidney cancer is the 14th most common cancer globally. The 5-year relative survival rate of kidney cancer at a localized stage is 92.9% and it declines to 17.4% in metastatic stage. Currently, the most accurate method of its diagnosis is tissue biopsy. However, the invasive and costly nature of biopsies makes it undesirable in many patients. Therefore, novel biomarkers for diagnosis and prognosis should be explored. Urinary extracellular vesicles (uEVs) are small vesicles (50–200 nm) in urine carrying nucleic acids, proteins and lipids as their cargos. These uEVs’ cargos can provide non-invasive alternative to monitor kidney health. In this review, we have summarized recent studies investigating potential use of uEVs’ cargos as biomarkers in kidney cancer for diagnosis, prognosis and therapeutic intervention.

show abstract

“…[4] A recent study indicates that stereotactic body radiation therapy (SBRT) and immunotherapy are promising therapeutic modalities for RCC, especially immunotherapy because RCC is highly immunogenic. [5] Immunotherapy aims to employ the immune system to kill cancer cells and has been a focus in the field of tumor therapy in recent years. [6] To date, a total of 6 programmed cell death protein 1 (PD-1) inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitors have been approved by the FDA for the treatment of metastatic melanoma, metastatic non-small cell lung cancer, classic Hodgkin's lymphoma, advanced urothelial carcinoma, and metastatic colorectal cancer, achieving excellent anti-tumor efficacy.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

TIGIT may Serve as a Potential Target for the Immunotherapy of Renal Cell Carcinoma

Hong,

Yu,

et al. 2023

Advanced Biology

View full text Add to dashboard Cite

This study aims to explore whether TIGIT is an effective target for the immunotherapy of renal cell cancer (RCC) with PD‐1 as a positive control. The expression of TIGIT and PD‐1 in RCC and peripheral blood mononuclear cells (PBMC) and the correlation between TIGIT and PD‐1 are evaluated. The expression of TIGIT and PD‐1 is inhibited, and then the proliferation, apoptosis, and migration are assessed. TIGIT expression is positively related to the expression of PDCD1, BTLA, ICOS, and FOXP3 (p < 0.05). TIGIT expression in the PBMC, TIL, RCC, and adjacent normal tissues is higher than PD‐1 expression. Blocking the TIGIT and PD‐1 signaling pathways significantly inhibits the proliferation, migration, and invasion of RCC cells and promotes their apoptosis. These effects are more evident in TIGIT inhibitors than in PD‐1 inhibitors. TIGIT inhibitor mainly regulates the expression of differential genes to achieve the reconstruction of immune killing and restore the killing effect on the RCC, and its mechanism by which TIGIT functions overlap that of PD‐1 inhibitor. TIGIT may become a target for the immunotherapy of RCC, and there is a theoretical basis for the combination of TIGIT inhibitors and PD‐1 inhibitors for the treatment of RCC.

show abstract

Stereotactic Body Radiotherapy for Localized Kidney Cancer

Cited by 6 publications

References 75 publications

“Could Patient Age and Gender, along with Mass Size, Be Predictive Factors for Benign Kidney Tumors?”: A Retrospective Analysis of 307 Consecutive Single Renal Masses Treated with Partial or Radical Nephrectomy

“Could Patient Age and Gender, along with Mass Size, Be Predictive Factors for Benign Kidney Tumors?”: A Retrospective Analysis of 307 Consecutive Single Renal Masses Treated with Partial or Radical Nephrectomy

Kidney Cancer and Potential Use of Urinary Extracellular Vesicles

TIGIT may Serve as a Potential Target for the Immunotherapy of Renal Cell Carcinoma

Contact Info

Product

Resources

About